By Charlie Smith

Growing body of research shows patients with addiction, PTSD, and depression can benefit from psychedelic substances

Numinus Wellness chief medical officer Dr. Evan Wood cautions that it’s not a cure for everybody—but trials have shown statistically significant results

0

Cannabis stocks soar—and New York tabloid ties this to study on COVID-19 prevention

The market capitalizations of Aurora, Tilray, Canopy Growth, Aphria, Cronos Group, and Hexo are all sharply higher than they were seven days earlier.

0

Vancouver-based Numinus Wellness hires addiction expert Dr. Evan Wood as chief medical officer

Most recently, Wood has headed the British Columbia Centre on Substance Use, which offers clinical guidance to medical practitioners

0

Aurora Cannabis shares spike in early trading following Reliva CBD takeover

Earlier this month, one financial writer described the company as the poster child of the legal weed industry’s woes.

0

Aurora Cannabis shares shoot up on positive quarterly numbers

Our roundup of cannabis stocks shows some improvement for Canopy Growth Corporation after a shakeup in the corporate office, but it was humdrum week for Tilray, Cronos Group, and Aphria.

0

Pandemic forces Portland activists to change tactics in seeking decriminalization of psychedelics in the city

There’s also a statewide proposal, IP 34, seeking access to licensed psilocybin therapy in Oregon.

0